Open Access CORRECTION

Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer

Yali Yi^{1,2†}, Jing Cai^{1,2†}, Peng Xu^{1,2}, Le Xiong^{1,2}, Zhiqin Lu^{1,2}, Zhimin Zeng^{1,2*} and Anwen Liu^{1,2*}

Correction to: Journal of Translational Medicine (2022) 20:122 https://doi.org/10.1186/s12967-022-03331-9

Following publication of the original article [1], we have been notified that there is an error in the title of the article. The correct title should as per below:

Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-smallcell lung cancer.

The original article has been corrected.

Author details

¹Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China. ²Jiangxi Key Laboratory of Clinical Translational Cancer Research, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China.

Published online: 27 June 2022

Reference

Yi Y, Cai J, Xu P, Xiong L, Lu Z, Zeng Z, Liu A. Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer. J Transl Med. 2022;20:122. https://doi.org/10. 1186/s12967-022-03331-9.

The original article can be found online at https://doi.org/10.1186/s12967-

 $^{\dagger}\text{Yali}\,\text{Yi}$ and Jing Cai are co-first authors and contributed equally to this work

*Correspondence: 2zm@163.com; awliu666@163.com

¹ Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China Full list of author information is available at the end of the article



Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

022-03331-9.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecom-

mons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.